Oxford Nanopore Technolo... Share Discussion Threads

[bamboo2] 25/10/2023 11:17

Hi CousinIT, The customer panel I find compelling. Could you PM me the section? It's at approx 1hr 30min

These are four seasoned professionals that have been using the kit for over five years each. I'd like to be able to take some quotes from them.

Jonathon Edgeworth seemed to be suggesting that a wider implementation of respiratory metagenomics in the NHS was imminent.

[cousinit] 25/10/2023 10:55

I get the transcripts from TIKR. Presume it uses AI to put it together as some word substitutions are obviously wide of the mark! (one reason why it takes a while to read...)

Any particular sections or terms you're looking for, as it is massive?

[bamboo2] 25/10/2023 07:25

CousinIT do you have a link for the CMD transcript? tia

I re-watched the Customer Panel again. It's really worth seeking this out.
Danny Miller and Andrew Beggs had some particularly interesting views on Grail.


If you get the vid up to view, after it has run a few minutes [or scroll forward], an options menu appears, that allows you to jump from section to section.

[bamboo2] 25/10/2023 07:11

74tom, eeza, Unless we see some large delayed trades coming through this week, then you are correct in saying they had already been active in the market. [I guess someone could have got the figures on the TR-1 wrong...]

No need to TR-1 under 5% for foreign holders. [Anyone know why this is? Is it to save on the cost of a stamp?]

[eeza] 24/10/2023 12:41

Can't see from the recent trading where they could have bought ~30m in the market.

[74tom] 24/10/2023 12:16

Presumably they already held most of the 30m shares but didn't need to TR1 because they were under the 5% international threshold?

[bamboo2] 24/10/2023 12:07

bioMerieux TR-1 announces total holding 59,062,832 or 6.880000%

Their max limit without prior agreement is 9.99%

Direct subscription to the co. was 29,025,326 shares.

Therefore 30,037,506 shares bought in the market.

[bamboo2] 24/10/2023 07:18

Leo, page 145 of the Annual Report 2022 [Paper edition]

[leoboy] 23/10/2023 17:47

ta am aware of post 1 - i normally find the info as i posted ; thought it was a legal thing ?

[bamboo2] 23/10/2023 17:39

Leo, spend a bit of time reading post 1 on this thread.

It's not totally accurate but it's a very good start.

It's also a historical record of changes to the significant holders.

[leoboy] 23/10/2023 17:37

cannot see list of shareholders - on web site ? nor in A/R 2022 ?

Is it me ?

[74tom] 23/10/2023 14:28

"TBF, This is a story share, with a massed army of shorts who refuse to believe that any UK listed company of this nature has any sort of future. They are not even bothered if they are wrong, because to them, it's a numbers game."

Absolutely nails the current prognosis here.

Watched the CMD presentation, it's utterly absorbing stuff. If ONT remains independent until the early 2030's then the sky is the limit here. As others have said, it's hard to know where to start from a discussion point of view.

I particularly liked the sheer enthusiasm of Andrew Beggs & his belief that in 10 years every smart phone will have a nanopore sequencer to self diagnose / monitor your own health. This can become ubiquitous, both in industry & from a personal point of view. A fascinating share to hold.

[cousinit] 23/10/2023 11:12

Quite a full CM day. It took me 90 mins to read through the transcript.

Analysts clearly expect Roche to launch their Nanopore offering (although ONT countered that it had been 'imminent' for some time now).

The diagnostic and applied potential being discussed looks like it has long way to run. The partnership model ONT are developing seems sensible. Less time to market, being integrated with existing/respected players and (I'm assuming) reducing ONT development costs.

[bamboo2] 23/10/2023 07:46

We might start to see some buying from bioMerieux from today.

23 OCTOBER 2023

Oxford Nanopore Technologies plc ("Oxford Nanopore" or "the Company")

Admission to Trading on the London Stock Exchange

Further to the announcement on 19 October 2023 in connection with the subscription for 29,025,326 ordinary shares in the capital of the Company (the " Shares ") by bioMérieux SA , Oxford Nanopore Technologies plc announces that the Shares have today been admitted to the standard listing segment of the Official List of the Financial Conduct Authority and to trading on the main market for listed securities of the London Stock Exchange under the ticker 'ONT'.

=======================

23 October 2023

Oxford Nanopore Technologies plc (the "Company")

Issue of Equity and Total Voting Rights

The Company today announces in respect of the period from 1 October to 23 October 2023, the issue of 29,200,350 ordinary shares of GBP0.0001 each ("Ordinary Shares"), following the subscription for 29,025,326 Ordinary Shares by bioMérieux SA in addition to the exercise of options granted under the Company's share option plans and issuance of shares under certain of the Company's remuneration schemes.

Such Ordinary Shares were also admitted to the Official List of the Financial Conduct Authority ("FCA") and to trading on the London Stock Exchange's main market for listed securities.

175,024 ordinary Shares issued under the share option plans and remuneration schemes were made under the Company's block listing facility. Following this issue, the Company has the ability to admit a further 23,806,369 Ordinary Shares under its block listing facility.

In accordance with the FCA's Disclosure Guidance and Transparency Rule 5.6.1, the Company announces that as at 23 October 2023, the Company's issued share capital consisted of 858,389,478 Ordinary Shares, one class A limited anti-takeover ("LAT") share of GBP1.00, one class B LAT share of GBP1.00 and one class C LAT share of GBP1.00. The Company did not hold any shares in treasury. Only the Ordinary Shares are voting shares and each such Ordinary Share carries one vote per Ordinary Share. Accordingly, the total number of voting rights in the Company as at 23 October 2023 is 858,389,478. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

[bamboo2] 23/10/2023 07:45

Capital Markets Day video is available on the co website.

[bamboo2] 21/10/2023 07:16

Catching up on some of the media reports of the past few days...

Oxford Nanopore Nabs £70M Investment From BioMérieux, Signs Clinical Collaboration With Mayo Clinic

Oct 19, 2023 | staff reporter



NEW YORK – Oxford Nanopore Technologies said on Thursday that it is receiving a £70 million ($84.6 million) strategic investment from French in vitro diagnostics firm BioMérieux. Separately, the UK-based nanopore sequencing technology firm said it has teamed up with the Mayo Clinic to develop new clinical tests to improve treatment of cancer and genetic disorders.

For its investment, BioMérieux is purchasing 29,025,326 ordinary shares of Oxford Nanopore — equivalent to 3.5 percent of the firm's voting rights — at a price of 238.08 pence per share, representing an investment of nearly £70 million. The deal is expected to close on Oct. 23.

In addition, BioMérieux expects to purchase up to 3.5 percent of Oxford Nanopore shares over time, subject to availability and price.

BioMérieux has further promised not to acquire more than 9.9 percent of Oxford Nanopore's shares in total in the next five years and not to sell any shares in the company for the next 12 months.

The deal builds on a collaboration agreement the two firms signed earlier this year for the development of infectious disease diagnostics.

The companies said they plan to combine Oxford Nanopore's sequencing-based in vitro diagnostics technology and BioMérieux's expertise in R&D, regulatory issues, and medical and market access. As part of the agreement, they will establish an IVD advisory board to help advance nanopore technology into routine clinical care.

"This investment will enable us to deliver rapid, accessible, and affordable clinical tools more quickly to address unmet needs and improve healthcare worldwide," Oxford Nanopore CEO Gordon Sanghera said in a statement.

"[T]he new generation of sequencing technology developed by Oxford Nanopore holds promise to answer future diagnostic needs and will further improve patient care, in particular against the ever-growing infectious diseases threat," said BioMérieux CEO Pierre Boulud.

Meanwhile, the partnership between Oxford Nanopore and Mayo Clinic, the financial details of which were not disclosed, is a multiyear collaboration. The goal is to develop new clinical tests in different areas, ranging from translational research in human genetics to genetic cancer predisposition detection. Projects will take place on Mayo Clinic's campus in Rochester, Minnesota.

"We have long held the ambition to become a utility player in world-renowned, global clinical centers of excellence, and this is our first step toward achieving that vision," Sanghera said in a statement.

"Pairing Oxford Nanopore's innovative nanopore sequencing with Mayo Clinic's world-class clinical and diagnostic testing knowledge further helps advance patient care," added Bobbi Pritt, interim chair of Mayo Clinic's Department of Laboratory Medicine and Pathology.

[bamboo2] 21/10/2023 06:36

From the above report...

"...JP Morgan analyst James Gordon, who attended the event, wrote in a note to investors that it feels like the company "has turned a corner" with technological development now mostly complete and commercialization stepping up. "Though we believe there is still further detail to be fleshed out on this expansion, we see the company as well placed to deliver very strong topline growth for many years and we also came away with increased confidence in the company's ability to also deliver on the plans to reach profitability," Gordon noted..."

[bamboo2] 21/10/2023 06:26

Oxford Nanopore Technologies Outlines Plans to Expand Presence in Clinical, Applied Markets

Oct 20, 2023 H Zhang
Premium

Use link for complete article


NEW YORK – Hosting its inaugural Capital Markets Day event in London on Thursday, Oxford Nanopore Technologies delineated its ambition and strategies to further penetrate the clinical and applied markets with its nanopore sequencers.

The company set the stage for the webcast event, which was open to institutional investors and financial analysts, by announcing its newly minted collaboration with Mayo Clinic and a £70 million ($84.6 million) strategic investment deal from French in vitro diagnostics firm BioMérieux.

"As clinical lab networks globally are expanding, we see this as a key opportunity for nanopore sequencing to enter clinical and diagnostics markets," Emma Stanton, Oxford Nanopore's Clinical VP, told investors.

According to Stanton, the company's collaboration with Mayo will first focus on breast cancer, specifically for the detection of BRAC1 and BRCA2 mutations. The collaborators are also interested in working on sequencing assays for rare cancers and infectious diseases.

For its partnership with BioMérieux, Stanton said the companies are working together to roll out a nanopore sequencing-based test for the rapid identification and characterization of drug-resistant tuberculosis. Besides that, she said they are working to validate nanopore data on BioMérieux's EPISeq software, which is used for hospital infectious disease surveillance and outbreak monitoring.

Furthermore, Stanton said Oxford Nanopore and BioMérieux will co-develop an IVD reflex test for clinical pathogen identification using targeted amplicon sequencing.

"We always look for things that are faster, give more actionable information, and are easier to use," said Mark Miller, executive vice president and chief medical officer of BioMérieux. "It's natural for us to then take the next step and want to collaborate and develop products [with Oxford Nanopore] that really start impacting patients and infectious diseases."

When asked by investors whether nanopore sequencing would undermine the company's existing BioFire multiplex PCR platform for infectious disease testing, Miller asserted that the former is "not cannibalistic at all" but rather "very complimentary and additive" to the company's product portfolio.

"I don't think that with multiplex PCR you are going to achieve the degree of confidence in tuberculosis and tuberculosis [antibiotic] resistance that you will with nanopore sequencing," he said. "Nanopore sequencing gives you a vast number of genes and mutations that are relevant for antibiotic resistance on the most commonly used drugs, which we cannot obtain right now with multiplex PCR, and we are not going for."

Overall, Stanton said the newly announced partnerships fit into the four pillars of Oxford Nanopore''s clinical strategy. These include collaborating with leading clinical institutions, deploying a dedicated clinical commercial sales team, developing end-to-end diagnostic solutions, and forging commercial partnerships with diagnostics firms that have established expertise, commercial presence, and market access.

Additionally, she pointed out that the top three clinical and diagnostic market segments for Oxford Nanopore are oncology, human genetics diseases, and infectious disease.

Still, all of Oxford Nanopore's products currently are developed for research use only, although labs can leverage them to develop and validate their own laboratory-developed tests (LDTs), Stanton said. To that end, she noted that the company will eventually need to have a "more prescribed and documented approach" for its products to achieve regulatory compliance such as IVDR marking and US Food and Drug Administration approval.

However, the company declined to comment on which product it plans to seek regulatory approval for first, and it did not disclose a concrete timeline.

During the event, Louisa Ludbrook, Oxford Nanopore's VP of commercial market development, accentuated the company's so-called Q-Line sequencing portfolio, which includes ISO9001-certified, locked-down versions of instruments and sample prep reagents to help industrial or clinical customers who desire to implement long-term and stabilized nanopore sequencing workflows.

She also highlighted the company's ongoing partnerships in industrial markets. These include a collaboration with PathoQuest, a next-generation sequencing-based biosafety testing firm, to commercialize tests for biomanufacturing quality control — both good manufacturing practices (GMP)-validated and non-GMP. According to her, the non-GMP assay is now available while the GMP-validated test is expected to launch in early 2024.

In addition, she said the company is working with the Base facility within the University of Queensland in Australia for nanopore sequencing-based mRNA vaccine quality control testing. "Together we'll develop a rapid, comprehensive direct RNA sequencing test suitable for industry use, and we're currently in discussions regarding commercial evaluation of this test," Ludbrook told investors.

As Oxford Nanopore moves into the clinical diagnostic and applied markets, the company is also focusing heavily on partnerships and collaborations to share resources, build new nanopore sequencing-based products, and equally reap the benefits, said Oxford Nanopore's senior VP of corporate and business development John Schoellerman.

It remains to be seen how much penetration into the clinical market the company can achieve in the near term, especially given the increasingly competitive next-generation sequencing landscape.

In 2021, the company established a subsidiary called Oxford Nanopore Diagnostics to help develop validated clinical diagnostic tools harnessing nanopore sequencing. However, the company has largely remained quiet since its inception, and Oxford Nanopore's 2022 annual report listed the subsidiary's principal activity as "dormant."

Oxford Nanopore did not respond to a request to comment on the future role Oxford Nanopore Diagnostics will play in helping the company go after clinical markets.

When asked about what percentage of the company's current revenues are directly related to the clinical diagnostic segments during the Q&A portion of the event, CEO Gordon Sanghera said, "If we define clinical as not discovery and translational, then I would say very little."

"It's too early to figure out what that looks like, as we're at the beginning in the foothills of these tests," he added.

JP Morgan analyst James Gordon, who attended the event, wrote in a note to investors that it feels like the company "has turned a corner" with technological development now mostly complete and commercialization stepping up. "Though we believe there is still further detail to be fleshed out on this expansion, we see the company as well placed to deliver very strong topline growth for many years and we also came away with increased confidence in the company's ability to also deliver on the plans to reach profitability," Gordon noted.

Commenting on competition in the nanopore sequencing space, Sanghera said while there is a rumor that Roche might launch a platform imminently, "we have not seen anything yet." Still, he said the company's "highly differentiated platform has significant first-mover advantage," and its "evergreen" IP portfolio has managed to "defend our position and block entrants."

In that regard, he also pointed to upcoming product launches, including TurBot, a benchtop device capable of "fully hands off" sample extraction, library prep, sequencing, and data analysis, as well as TraxIon, a hand-held device also capable of carrying out the end-to-end nanopore sequencing workflow.

He also teased the audience with a so-called voltage chip that the company is developing, which will come with 10,000 to 100,000 channels and "ultimately lead to a one-hour, $10 genome."

"Don't ask me when that's going to happen," Sanghera said. "It's three to five years out."

[bamboo2] 20/10/2023 08:29

TBF, This is a story share, with a massed army of shorts who refuse to believe that any UK listed company of this nature has any sort of future. They are not even bothered if they are wrong, because to them, it's a numbers game.

I reckon it's time to relax and count yourself lucky you have a share in the best sequencing business in the world.

[the big fella] 20/10/2023 07:05

A fairly lukewarm reception of yesterday's news. Share price trading almost 10% below the price they paid and still under pressure it seems.

[bamboo2] 19/10/2023 19:25

I have to say that the CMD was a marathon.
So much detail, almost too much to take in.
This co. is really going places. Wow!

It was a shame the market closed early due to a fault at the LS exchange.


The webcast is not yet uploaded, but these are the slides.

[cousinit] 19/10/2023 10:02

Appreciate ONT is a bit of a different animal, but had a similar situation with OXB where a French Institute announced a similar market investment. They completed it in a matter of a few weeks, although it was announced coincident with results that were akin to 'clearing the decks' which no doubt drove volume...

[eeza] 19/10/2023 09:20

They are to buy another 3.5% taking them to 7%, but can go to 9.9% before further agreement is required.

So shorters' bots will be set to close out, imo. However, they don't just close their shorts as that would drive the share price up, so their algorithms will be to keep selling, to hold the SP, while buying back slightly more each time.